Results of non-medical switching from original infliximab to its Russian biosimilar in patients with ulcerative colitis
Non-medical switching from the original infliximab to its Russian biosimilar, as well as therapy with a biosimilar under one trade name, demonstrates similar clinical results compared to continuing to take the original molecule for the treatment of UC. The obtained data confirm the safety and efficacy of non-medical switching to infliximab in patients with UC.
Authors
- А И Парфенов (ORCID: https://orcid.org/0000-0002-9782-4860)
- О. В. Князев (ORCID: https://orcid.org/0000-0001-7250-0977)
- Maria Y. Timanovskaya (ORCID: https://orcid.org/0000-0002-7937-2346)
Institutions
- Moscow Clinical Scientific Center (RU)
Publication Details
- Journal
- Terapevticheskii arkhiv
- Published
- 2025-03-26
- DOI
- https://doi.org/10.26442/00403660.2025.02.203184
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00